Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Increases By 67.2%

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a large increase in short interest in July. As of July 31st, there was short interest totaling 1,200,354 shares, an increase of 67.2% from the July 15th total of 718,008 shares. Based on an average trading volume of 316,846 shares, the short-interest ratio is currently 3.8 days. Currently, 8.0% of the company’s stock are sold short.

Cel-Sci Stock Up 0.6%

NYSEAMERICAN CVM traded up $0.01 during trading on Monday, reaching $1.55. 129,421 shares of the company’s stock traded hands, compared to its average volume of 269,824. Cel-Sci has a 12-month low of $0.89 and a 12-month high of $13.48. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. The firm has a market cap of $27.09 million, a price-to-earnings ratio of -0.16 and a beta of 0.63. The company’s 50 day simple moving average is $1.23 and its two-hundred day simple moving average is $2.68.

Cel-Sci (NYSEAMERICAN:CVM) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.47) earnings per share for the quarter.

Institutional Trading of Cel-Sci

A number of institutional investors have recently modified their holdings of CVM. HighTower Advisors LLC bought a new stake in shares of Cel-Sci in the 4th quarter valued at about $53,000. HRT Financial LP purchased a new stake in Cel-Sci during the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new stake in Cel-Sci during the fourth quarter valued at approximately $66,000. US Bancorp DE acquired a new stake in Cel-Sci in the third quarter valued at approximately $80,000. Finally, Renaissance Technologies LLC acquired a new stake in Cel-Sci in the fourth quarter valued at approximately $81,000. 12.08% of the stock is currently owned by institutional investors.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.